SG11202102629WA - Dual acting cd1d immunoglobulin - Google Patents
Dual acting cd1d immunoglobulinInfo
- Publication number
- SG11202102629WA SG11202102629WA SG11202102629WA SG11202102629WA SG11202102629WA SG 11202102629W A SG11202102629W A SG 11202102629WA SG 11202102629W A SG11202102629W A SG 11202102629WA SG 11202102629W A SG11202102629W A SG 11202102629WA SG 11202102629W A SG11202102629W A SG 11202102629WA
- Authority
- SG
- Singapore
- Prior art keywords
- cd1d
- immunoglobulin
- dual acting
- dual
- acting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2021664 | 2018-09-19 | ||
| PCT/NL2019/050624 WO2020060405A1 (en) | 2018-09-19 | 2019-09-19 | Dual acting cd1d immunoglobulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102629WA true SG11202102629WA (en) | 2021-04-29 |
Family
ID=63834616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102629WA SG11202102629WA (en) | 2018-09-19 | 2019-09-19 | Dual acting cd1d immunoglobulin |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210371525A1 (en) |
| EP (2) | EP3853255A1 (en) |
| JP (2) | JP2022501377A (en) |
| KR (1) | KR20210062051A (en) |
| CN (2) | CN113260629A (en) |
| AU (1) | AU2019344300A1 (en) |
| BR (1) | BR112021005184A8 (en) |
| CA (2) | CA3113605A1 (en) |
| EA (1) | EA202190773A1 (en) |
| MX (1) | MX2021003234A (en) |
| SG (1) | SG11202102629WA (en) |
| WO (2) | WO2020060406A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3792283A1 (en) * | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| CN116209456A (en) * | 2020-08-14 | 2023-06-02 | 伽马三角洲疗法有限公司 | Multispecific anti-TCR delta variable 1 antibodies |
| CA3200826A1 (en) | 2020-12-10 | 2022-06-16 | Paul Willem Henri Ida PARREN | Antibodies that bind gamma-delta t cell receptors |
| WO2022175414A1 (en) * | 2021-02-17 | 2022-08-25 | Adaptate Biotherapeutics Ltd. | Multispecific anti-tcr delta variable 1 antibodies |
| EP4298125A1 (en) | 2021-02-26 | 2024-01-03 | LAVA Therapeutics N.V. | Antibodies that bind cd123 and gamma-delta t cell receptors |
| WO2023037333A1 (en) * | 2021-09-13 | 2023-03-16 | Janssen Biotech, Inc | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
| WO2023067138A1 (en) * | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| CN116731166A (en) * | 2021-12-22 | 2023-09-12 | 北京世纪沃德生物科技有限公司 | CRP camel-derived single domain antibody and preparation method and application thereof |
| CA3208653A1 (en) * | 2022-02-17 | 2022-08-25 | Mihriban Tuna | Multispecific anti-tcr delta variable 1 antibodies |
| WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
| WO2023186905A1 (en) | 2022-03-29 | 2023-10-05 | LAVA Therapeutics N.V. | A method of treating a hematological cancer following screening for cd1d positive tumor cells |
| EP4285926A1 (en) * | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| CN116143934B (en) * | 2023-03-21 | 2023-07-25 | 诺赛联合(北京)生物医学科技有限公司 | Stem cell exosome extraction kit and application thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP5677972B2 (en) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | Human serum albumin linker and its conjugates |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| KR101224468B1 (en) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | Bispecific antibody having a novel form and use thereof |
| ES2537207T3 (en) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| EP2766042A4 (en) * | 2011-10-14 | 2015-05-27 | Teva Pharmaceuticals Australia Pty Ltd | ANTIBODIES TO CD1d |
| ES2743399T3 (en) | 2012-04-20 | 2020-02-19 | Merus Nv | Methods and means for the production of Ig-like heterodimeric molecules |
| CA2892193C (en) | 2012-11-21 | 2018-06-19 | Pharmabcine Inc. | Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same |
| JP6617138B2 (en) * | 2014-04-10 | 2019-12-11 | ラヴァ・セラピューティクス・ベー・フェー | Immunoglobulin binding to human Vγ9Vδ2 T cell receptor |
| KR20170021354A (en) * | 2014-07-02 | 2017-02-27 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas |
| EP3250608A1 (en) * | 2015-01-27 | 2017-12-06 | Lava Therapeutics B.V. | Single domain antibodies targeting cd1d |
| CN108289902B (en) * | 2015-09-09 | 2022-05-20 | 清华大学 | Inhibitors of the mevalonate pathway as highly effective vaccine adjuvants |
| KR102519861B1 (en) * | 2016-05-12 | 2023-04-10 | 아디셋 바이오, 인크. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
-
2019
- 2019-09-19 US US17/277,984 patent/US20210371525A1/en active Pending
- 2019-09-19 EP EP19828845.8A patent/EP3853255A1/en active Pending
- 2019-09-19 JP JP2021515548A patent/JP2022501377A/en active Pending
- 2019-09-19 JP JP2021515488A patent/JP7457007B2/en active Active
- 2019-09-19 KR KR1020217011582A patent/KR20210062051A/en active Search and Examination
- 2019-09-19 CN CN201980076078.2A patent/CN113260629A/en active Pending
- 2019-09-19 BR BR112021005184A patent/BR112021005184A8/en unknown
- 2019-09-19 AU AU2019344300A patent/AU2019344300A1/en active Pending
- 2019-09-19 MX MX2021003234A patent/MX2021003234A/en unknown
- 2019-09-19 WO PCT/NL2019/050625 patent/WO2020060406A1/en unknown
- 2019-09-19 EP EP19831921.2A patent/EP3853256A1/en active Pending
- 2019-09-19 CN CN201980076077.8A patent/CN113272325A/en active Pending
- 2019-09-19 CA CA3113605A patent/CA3113605A1/en active Pending
- 2019-09-19 US US17/277,906 patent/US20220111043A1/en active Pending
- 2019-09-19 SG SG11202102629WA patent/SG11202102629WA/en unknown
- 2019-09-19 EA EA202190773A patent/EA202190773A1/en unknown
- 2019-09-19 CA CA3113409A patent/CA3113409A1/en active Pending
- 2019-09-19 WO PCT/NL2019/050624 patent/WO2020060405A1/en active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021003234A (en) | 2021-07-16 |
| WO2020060406A1 (en) | 2020-03-26 |
| US20220111043A1 (en) | 2022-04-14 |
| JP2022501377A (en) | 2022-01-06 |
| WO2020060405A1 (en) | 2020-03-26 |
| CA3113605A1 (en) | 2020-03-26 |
| BR112021005184A8 (en) | 2022-08-16 |
| EP3853256A1 (en) | 2021-07-28 |
| BR112021005184A2 (en) | 2021-06-08 |
| CA3113409A1 (en) | 2020-03-26 |
| CN113260629A (en) | 2021-08-13 |
| US20210371525A1 (en) | 2021-12-02 |
| KR20210062051A (en) | 2021-05-28 |
| JP7457007B2 (en) | 2024-03-27 |
| CN113272325A (en) | 2021-08-17 |
| EP3853255A1 (en) | 2021-07-28 |
| JP2022501369A (en) | 2022-01-06 |
| EA202190773A1 (en) | 2021-06-21 |
| AU2019344300A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202102629WA (en) | Dual acting cd1d immunoglobulin | |
| IL279321A (en) | Anti-sirpα antibody | |
| IL280780A (en) | Anti-tigit antibodies | |
| IL279235A (en) | Dll3-cd3 bispecific antibodies | |
| EP3387442A4 (en) | Humanized anti-cd73 antibodies | |
| IL279352A (en) | Il-11ra antibodies | |
| IL280013A (en) | Anti-il36r antibodies | |
| IL283812B (en) | Humanized anti-human-pd-1 antibody | |
| IL278010A (en) | Galectin-10 antibodies | |
| EP3380524A4 (en) | Humanized anti-cll-1 antibodies | |
| IL282756A (en) | Humanized anti-sirpα antibodies | |
| IL277030A (en) | Antibodies | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| ZA202004908B (en) | Bispecific antibody | |
| SG11202106171WA (en) | Anti-btla antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| GB201811368D0 (en) | Antibody | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| IL282355A (en) | Exosome-targeting bispecific antibodies | |
| GB201817172D0 (en) | Antibody | |
| EP3693013A4 (en) | Bispecific antibody | |
| GB201806084D0 (en) | Antibodies | |
| SG11202009267QA (en) | Anti-vegfr-2 antibody | |
| GB201813597D0 (en) | Antibody | |
| GB201819952D0 (en) | Antibodies |